Clareo Health | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo for a period of 4 months followed by safety monitoring for an additional 4 months after the last dose
Age
18–57
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of Secondary Progressive Multiple Sclerosis
Aged 18 to 57 years old, at the time of informed consent
You may not be if
History of clinically important (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or hematologic insufficiency or any other major disease other than MS ( Multiple Sclerosis)
Inability in the opinion of the Investigator to comply with study requirements
